WATERTOWN, Mass. -- V.I. Technologies, Inc., a biotechnology company dedicated to developing products that improve the safety of the blood supply by pathogen reduction, announced today that its Inactine pathogen reduction system for red blood cells was successful in inactivating the virus that causes Severe Acute Respiratory Syndrome (SARS). The research demonstrated eradication of both the Asian and Toronto strains of the SARS virus in red blood cells experimentally contaminated with high titers of the deadly virus.
The SARS inactivation study will be presented by Vitex at the National Heart, Lung, and Blood Institute Workshop on Pathogen Reduction and Blood Component Safety: Critical Issues and Decision Making on July 31, 2003 in Bethesda, Md.
Although the SARS virus has yet to be demonstrated to be transmitted via a blood transfusion, the concern for such transmission has been heightened by its detection in blood. The World Health Organization (WHO) issued recommendations on blood donor deferrals for individuals in areas with recent local transmission of the disease and travelers to those areas. Similar guidance was provided by the FDA earlier this year.
"The SARS virus is an example of an emerging pathogen that can potentially affect the safety of the world's blood supply," said John Barr, president and CEO of Vitex. "This data gives us confidence that, if the Inactine pathogen reduction technology were in place, it could prevent the transmission of this infectious agent by blood transfusion. Our virology staff continues to perform cutting edge research to demonstrate the viral inactivation power of the Inactine technology."
SARS is a respiratory illness with high morbidity and mortality that has been recently reported in Asia, North America and Europe. The recently identified cause of SARS is a coronavirus that has only recently crossed a species barrier to infect humans. SARS is known to be spread by close personal contact. As of July 11, 2003, the WHO has reported cases in 32 countries.
Vitex is developing products designed to improve the safety of the world's blood supply. The company's proprietary Inactine technology, currently in Phase III clinical trials, is designed to inactivate a wide range of viruses, bacteria and parasites, and has demonstrated its ability to remove prion proteins, while preserving the therapeutic properties of red blood cells. The technology works by binding to the RNA or DNA of the pathogen. Once bound, the compound forms an irreversible bond to the pathogenic nucleic acid, preventing replication and thereby "killing" the pathogens.
Source: V.I. Technologies, Inc.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.